Novartis comes up with an answer for breast cancer with PI3K drug alpelisib
Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progression-free survival times for patients. Around 40% of HR+ advanced breast cancer patients have a PIK3CA mutation, making it a considerable piece for the overall market. As the drug is an alpha-specific, so the drug standouts. Also, it has lower toxicity, so, the majority of the patients can be on therapy for a longer time.
Epizyme files for first FDA filing wit...
